SecSonar.com

PTC Therapeutics, Inc. (PTCT)

PTC Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

PTC Therapeutics, Inc. (PTCT) is a Biotechnology company based in US with a market capitalization of $6.1B. Revenue grew 114.5% year-over-year and the company generated $702.3M in free cash flow. This page tracks PTCT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 939 employees · IPO Jun 20, 2013

Valuation

Valuation & price

$71.47 · as of May 17, 2026 · -17.1% vs 52w high

9.2

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$85.99$64.64$43.30Jul 25Dec 25Jul 26Jul 7, 25$47.98Jul 9, 25$48.74Jul 11, 25$48.55Jul 15, 25$47.75Jul 17, 25$48.53Jul 21, 25$47.86Jul 23, 25$47.08Jul 25, 25$44.74Jul 29, 25$49.29Jul 31, 25$52.11Aug 4, 25$52.25Aug 6, 25$51.36Aug 11, 25$43.30Aug 13, 25$48.17Aug 15, 25$48.82Aug 19, 25$49.59Aug 21, 25$48.92Aug 25, 25$49.30Aug 27, 25$49.78Aug 29, 25$49.33Sep 3, 25$55.55Sep 5, 25$57.26Sep 9, 25$58.42Sep 11, 25$60.96Sep 16, 25$59.69Sep 18, 25$62.88Sep 22, 25$60.85Sep 24, 25$59.50Sep 26, 25$58.99Sep 30, 25$61.37Oct 2, 25$63.02Oct 6, 25$64.80Oct 8, 25$64.48Oct 10, 25$66.23Oct 14, 25$66.09Oct 16, 25$66.82Oct 21, 25$67.17Oct 23, 25$66.80Oct 27, 25$67.08Oct 29, 25$67.35Oct 31, 25$68.31Nov 4, 25$67.72Nov 6, 25$72.59Nov 10, 25$72.48Nov 12, 25$74.95Nov 14, 25$75.30Nov 18, 25$76.69Nov 20, 25$76.46Nov 25, 25$82.93Nov 28, 25$85.99Dec 2, 25$78.50Dec 4, 25$77.85Dec 8, 25$76.91Dec 10, 25$74.10Dec 12, 25$75.64Dec 16, 25$75.42Dec 18, 25$74.59Dec 22, 25$78.90Dec 24, 25$78.37Dec 29, 25$77.64Jan 2, 26$76.74Jan 6, 26$76.70Jan 8, 26$76.85Jan 12, 26$77.59Jan 14, 26$77.29Jan 16, 26$72.48Jan 21, 26$75.56Jan 23, 26$75.25Jan 27, 26$75.49Jan 29, 26$76.43Feb 2, 26$74.88Feb 4, 26$73.91Feb 9, 26$74.16Feb 11, 26$70.92Feb 13, 26$69.45Feb 18, 26$68.93Feb 20, 26$70.66Feb 24, 26$68.98Feb 26, 26$68.10Mar 2, 26$66.37Mar 4, 26$64.29Mar 6, 26$62.82Mar 10, 26$68.56Mar 12, 26$63.36Mar 17, 26$67.45Mar 19, 26$67.08Mar 23, 26$66.42Mar 25, 26$66.75Mar 27, 26$66.13Mar 31, 26$68.13Apr 2, 26$67.77Apr 7, 26$69.58Apr 9, 26$70.85Apr 13, 26$70.42Apr 15, 26$73.57Apr 17, 26$72.43Apr 22, 26$70.85Apr 24, 26$68.23Apr 28, 26$70.26Apr 30, 26$65.06May 4, 26$65.49May 6, 26$66.57May 8, 26$73.69May 12, 26$75.02May 14, 26$72.72May 18, 26$70.15May 20, 26$71.02May 22, 26$68.81May 28, 26$71.05Jun 1, 26$73.80Jun 3, 26$68.68Jun 5, 26$70.97Jun 9, 26$73.68Jun 11, 26$74.71Jun 15, 26$76.77Jun 17, 26$78.53Jun 22, 26$80.96Jun 24, 26$84.41Jun 26, 26$84.43Jul 2, 26$81.91
$43.3052-week range$86.25
Loading valuation history…

Fundamentals

Key fundamentals

$6.1B

Market cap

114.5%

Revenue growth (YoY)

95.8%

Gross margin

$702.3M

Free cash flow (USD)

-$1.5B

Net debt

Net cash position

3.5%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$82.7MFY 2017$194.4MFY 2018$264.7MFY 2019$307.0MFY 2020$380.8MFY 2021$538.6MFY 2022$698.8MFY 2023$937.8MFY 2024$806.8MFY 2025$1.7B
$82.7M$1.7B

Free cash flow by year

2016 → 2025

FY 2016$-105.3MFY 2017$-13.2MFY 2018$-43.2MFY 2019$-144.1MFY 2020$-250.0MFY 2021$-336.7MFY 2022$-509.1MFY 2023$-279.0MFY 2024$-181.9MFY 2025$702.3M
-$105.3M$702.3M

Gross margin by year

2021 → 2025

FY 202194.0%FY 202293.6%FY 202393.0%FY 202492.9%FY 202595.8%
94.0%95.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

12

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $693K · 10b5-1 PlanAlmstead Neil Gregory · CHIEF TECHNICAL OPS OFFICER · $693.2KJun 30, 2026Filing
  • Insider sellInsider Sell $2.3M · 10b5-1 PlanAlmstead Neil Gregory · CHIEF TECHNICAL OPS OFFICER · $2.3MJun 26, 2026Filing
  • Insider sellInsider Sell $1.9M · 10b5-1 PlanAlmstead Neil Gregory · CHIEF TECHNICAL OPS OFFICER · $1.9MJun 24, 2026Filing
  • Insider sellInsider Sell $823K · 10b5-1 PlanBoulding Mark Elliott · EXEC. VP AND CLO · $822.9KJun 22, 2026Filing
  • Insider sellInsider Sell $1.5M · 10b5-1 PlanUtter Christine Marie · SVP, CHIEF ACCOUNTING OFFICER · $1.5MJun 22, 2026Filing
  • 8-K eventConvertible Notes IssuedJun 18, 2026Filing
  • 8-K eventConvertible Notes OfferingJun 16, 2026Filing
  • Insider sellInsider Sell $1.6M · 10b5-1 PlanPauwels Eric · CHIEF BUSINESS OFFICER · $1.6MJun 12, 2026Filing
  • 8-K eventConsulting Agreement SignedJun 9, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 5, 2026Filing

Questions

Frequently asked questions

What is PTC Therapeutics, Inc.'s market cap?

PTC Therapeutics, Inc. (PTCT) has a market capitalization of $6.1B.

What is PTCT's P/E ratio?

PTCT trades at a price-to-earnings ratio of 9.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

Are insiders buying PTCT stock?

SEC Form 4 filings show no open-market insider buys at PTC Therapeutics, Inc. in the last 90 days (12 sells).

Same arena

Related companies in Biotechnology

CNTA

Centessa Pharmaceuticals plc

$6.1B

RYTM

Rhythm Pharmaceuticals, Inc.

$6.2B

TGTX

TG Therapeutics, Inc.

$5.9B

PTGX

Protagonist Therapeutics, Inc.

$6.4B

KYMR

Kymera Therapeutics, Inc.

$6.7B

LQDA

Liquidia Corporation

$5.5B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.